Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,795 matching trials from the live ClinicalTrials.gov search.
Conditions
Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
Interventions
Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
Behavioral · Drug
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Spinal Cord Injuries, Tetraplegia, Cervical Spinal Cord Injury
Interventions
transcranial Random Noise Stimulation (tRNS), transcranial Direct Current Stimulation (tDCS), sham-stimulation
Other
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Shoulder Adhesive Capsulitis, Frozen Shoulder, Adhesive Capsulitis of Shoulder
Interventions
Translational manipulation, Manual therapy
Procedure
Lead sponsor
Daniel G. Rendeiro
Federal
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Conditions
Type 2 Diabetes
Interventions
Supportive Therapy (Control), Home DM-BAT
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Influenza A
Interventions
VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
129
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo, olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions
Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention
Other · Behavioral
Lead sponsor
Hospital de Clinicas de Porto Alegre
Other
Eligibility
7 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neuroendocrine Carcinoma, Neuroendocrine Tumors
Interventions
Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Dementia, Elderly, Sleep
Interventions
Control Condition, Individualized Social Activities (ISA), Physical Resistance Training and Walking (PRT/walking), Combined ISA/PRT/walking
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
55 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Completed Not applicable Interventional Results available

Anterior Cruciate Ligament Reconstruction and Plyometric Exercise

NCT01851655
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
Plyometric Exercise
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
15 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of a Nitrate Supplementation on Erectile Function

NCT06213077
Conditions
Erectile Dysfunction
Interventions
Nitric Oxide, Tadalafil, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
RHA Investments Ltd
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Actinic Keratosis
Interventions
Carac Cream, Placebo Cetaphil cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Low Back Pain, Myofascial Pain Syndromes
Interventions
Ischemic Compression, Low-Level Laser Therapy, Exercise Program, Sham Low-Level Laser Therapy
Other · Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Peripheral T Cell Lymphoma
Interventions
Belinostat Injection, Pralatrexate Injection, CHOP, COP
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
10
States / cities
Clovis, California • Santa Monica, California • Aurora, Colorado + 7 more
Completed Not applicable Interventional

RETAINWORKS Impact Evaluation

NCT05167981
Conditions
Disability
Interventions
RETAINWORKS
Other
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Topeka, Kansas
Conditions
Cancer
Interventions
Project Onward website + social network, Project Onward website
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
19 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Parkinson Disease
Interventions
Sham rTMS, Real rTMS, Supervised aerobic exercise
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
Interventions
bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Alcohol Use Disorder, Addiction
Interventions
TaskFlow Transcranial Electrical Stimulation device, Executive Function Focused Cognitive Training
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Tinnitus
Interventions
Tinnitus Masking, Tinnitus Retraining Therapy (TRT), Tinnitus Education (TED)
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon